A new report commissioned by industry group PhRMA lends credibility to the argument that a complex distribution system plays a role in high drug costs.

The leadership changes just keep on coming at GlaxoSmithKline. The latest? Global pharma president Abbas Hussain is out, and AstraZeneca vet Luke Miels is in.…

Here’s a radical solution for hepatitis C treatment in the U.S.: The government could buy Gilead Sciences. Price: $156 billion. Payoff: Curing hep C patients…

Pfizer CEO Ian Read says the “ethical” pharma industry he knows is nothing like notorious ex-CEO Martin Shkreli's work, and certainly isn't "…

Drug wholesaler McKesson will pay $150 million to settle with the Justice Department allegations that it did not monitor "suspicious" opioid orders…

The FDA rolled out new biosim interchangeability draft guidelines Tuesday. The gist? Winning the designation won't be easy, but a big payoff could await.

In a proposed pair of studies, the FDA will look at healthcare providers' and patients' responses to determine their ability to detect different…

Bayer’s $66 billion Monsanto takeover has plenty of critics. But thanks to an $8 billion R&D pledge, it has one key backer: U.S. President-elect Donald…

Astellas pulled the plug on a cell culture flu vaccine partnership with UMN Pharma after Japanese regulators stiff-armed its application for approval.

Pharma